Camurus AB (publ) (STO:CAMX)
739.50
-0.50 (-0.07%)
Nov 20, 2026, 5:29 PM CET
Camurus AB Revenue
Camurus AB had revenue of 724.01M SEK in the quarter ending September 30, 2026, with 27.67% growth. This brings the company's total for the last twelve months to 2.42B, up 2.96% year-over-year. In the year 2025, Camurus AB had annual revenue of 2.27B with 21.30% growth. That makes Camurus AB the 16,274th largest company in the world by revenue and 201st in Sweden.
Revenue (ttm)
2.42B
Revenue Growth
+2.96%
P/S Ratio
18.16
Revenue / Employee
7.50M
Employees
323
Market Cap
44.01B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Camurus AB breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.27B | 397.80M | 21.30% |
| Dec 31, 2024 | 1.87B | 150.73M | 8.78% |
| Dec 31, 2023 | 1.72B | 760.51M | 79.52% |
| Dec 31, 2022 | 956.34M | 355.77M | 59.24% |
| Dec 31, 2021 | 600.57M | 264.57M | 78.74% |
| Dec 31, 2020 | 336.00M | 230.39M | 218.16% |
| Dec 31, 2019 | 105.61M | 56.28M | 114.12% |
| Dec 31, 2018 | 49.32M | -4.99M | -9.18% |
| Dec 31, 2017 | 54.31M | -59.43M | -52.25% |
| Dec 31, 2016 | 113.74M | -41.06M | -26.53% |
| Dec 31, 2015 | 154.80M | -53.41M | -25.65% |
| Dec 31, 2014 | 208.21M | 10.49M | 5.31% |
| Dec 31, 2013 | 197.72M | 102.51M | 107.68% |
| Dec 31, 2012 | 95.20M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioArctic AB | 1.00B |
| Saniona AB | 424.56M |
| Hansa Biopharma AB | 301.64M |
| Genovis AB (publ.) | 145.23M |
| Egetis Therapeutics AB | 70.00M |
| Medivir AB | 8.51M |
| Vicore Pharma Holding AB | 3.83M |
| Flerie AB | 2.60M |
Camurus AB News
- 4 days ago - Camurus AB Transcript: Jefferies Global Healthcare Conference - Transcripts
- 4 days ago - Camurus AB Slides: Company presentation - Filings
- 17 days ago - Camurus AB Earnings Call Transcript: Q3 2026 - Transcripts
- 17 days ago - Camurus AB Slides: Q3 2026 - Filings
- 23 days ago - Camurus AB Slides: Company presentation - Filings
- 2 months ago - Camurus AB Slides: Company presentation - Filings
- 3 months ago - Camurus AB Slides: Company presentation - Filings
- 4 months ago - Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA - PRNewsWire